Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model
Hepatology, Volume 56, No. 3, Year 2012
Notification
URL copied to clipboard!
Description
MicroRNA-221 (miR-221) is one of the most frequently and consistently up-regulated microRNAs (miRNAs) in human cancer. It has been hypothesized that miR-221 may act as a tumor promoter. To demonstrate this, we developed a transgenic (TG) mouse model that exhibits an inappropriate overexpression of miR-221 in the liver. Immunoblotting and immunostaining confirmed a concomitant down-regulation of miR-221 target proteins. This TG model is characterized by the emergence of spontaneous nodular liver lesions in approximately 50% of male mice and by a strong acceleration of tumor development in 100% of mice treated with diethylnitrosamine. Similarly to human hepatocellular carcinoma, tumors are characterized by a further increase in miR-221 expression and a concomitant inhibition of its target protein-coding genes (i.e., cyclin-dependent kinase inhibitor [Cdkn]1b/p27, Cdkn1c/p57, and B-cell lymphoma 2-modifying factor). To validate the tumor-promoting effect of miR-221, we showed that in vivo delivery of anti-miR-221 oligonucleotides leads to a significant reduction of the number and size of tumor nodules. Conclusions: This study not only establishes that miR-221 can promote liver tumorigenicity, but it also establishes a valuable animal model to perform preclinical investigations for the use of anti-miRNA approaches aimed at liver cancer therapy. © 2012 American Association for the Study of Liver Diseases.
Authors & Co-Authors
Callegari, Elisa
Italy, Ferrara
University of Ferrara
Elamin, Bahaeldin Khalid
Italy, Ferrara
University of Ferrara
Sudan, Khartoum
Khartoum University
Giannone, Ferdinando Antonino
Italy, Bologna
Irccs Azienda Ospedaliero-universitaria Di Bologna
Milazzo, Maddalena
Italy, Bologna
Irccs Azienda Ospedaliero-universitaria Di Bologna
Altavilla, Giuseppe
Italy, Padua
Università Degli Studi Di Padova
Fornari, F.
Italy, Bologna
Irccs Azienda Ospedaliero-universitaria Di Bologna
Giacomelli, Luciano
Italy, Padua
Università Degli Studi Di Padova
D'Abundo, Lucilla
Italy, Ferrara
University of Ferrara
Ferracin, Manuela
Italy, Ferrara
University of Ferrara
Bassi, Cristian
Italy, Ferrara
University of Ferrara
Zagatti, Barbara
Italy, Ferrara
University of Ferrara
Corrà, Fabio
Italy, Ferrara
University of Ferrara
Miotto, Elena
Italy, Ferrara
University of Ferrara
Lupini, Laura
Italy, Ferrara
University of Ferrara
Bolondi, Luigi
Italy, Bologna
Irccs Azienda Ospedaliero-universitaria Di Bologna
Gramantieri, Laura
Italy, Bologna
Irccs Azienda Ospedaliero-universitaria Di Bologna
Croce, Carlo Maria
Italy, Ferrara
University of Ferrara
United States, Columbus
The Ohio State University Wexner Medical Center
Sabbioni, Silvia
Italy, Ferrara
University of Ferrara
Negrini, Massimo
Italy, Ferrara
University of Ferrara
Statistics
Citations: 156
Authors: 19
Affiliations: 5
Identifiers
Doi:
10.1002/hep.25747
ISSN:
02709139
Research Areas
Cancer
Participants Gender
Male